(3 Minutes Read)
Minister of Pharmaceutical Industry, Ouacim Kouidri, has officially inaugurated a significant new investment initiative spearheaded by the Saidal Group in the El Bouni industrial zone of Annaba. This ambitious project marks a pivotal step in Algeria’s strategy to locally manufacture vaccines that are part of the national immunisation program, reinforcing the country’s healthcare independence.
During his visit to the site, Minister Kouidri underscored the critical importance of adhering to established construction timelines and maintaining stringent quality standards throughout the development of the facility. He highlighted the strategic nature of the project, which is expected to not only reduce Algeria’s reliance on imported vaccines but also save the national treasury an estimated $150 million annually — a figure that could climb to USD 200 million as vaccine demand increases and production scales up.
In addition to overseeing the launch, the Minister shared news of Algeria’s growing regional engagement in the pharmaceutical sector. He announced the signing of multiple partnership agreements at the upcoming 2025 Intra-African Trade Fair (IATF), with total investments surpassing USD 725 million. These partnerships aim to enhance domestic pharmaceutical capabilities and foster integration into African and international markets.
Reassuring citizens amid growing global concern over medicine availability, Minister Kouidri confirmed that there are currently no shortages of essential drugs in Algeria — including critical cancer treatments — reflecting the government’s ongoing efforts to stabilise the supply chain.
Providing further insight into the vaccine production project, Saidal Group CEO Nabila Benyghzer outlined the facility’s scope and timeline. The plant will span an area of 22,267 square meters and is scheduled for completion within two years. Initial production will focus on vaccines required for Algeria’s national vaccination schedule. Later phases of the project, carried out in collaboration with the Pasteur Institute, will extend to the development of additional vaccine types.
Read Also;
https://trendsnafrica.com/who-allocates-one-million-mpox-vaccines-for-africa/
Beyond its healthcare impact, the project is expected to stimulate economic growth by generating employment opportunities and strengthening Algeria’s standing as a pharmaceutical hub in the region. Ultimately, this initiative reflects a broader vision to enhance national health security while contributing to the country’s industrial and economic development.
